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Abstract
The objective of the present study was to assess the effect of adding specific prebiotics to standard formula feeding on the number of fever
episodes in the first year of life. In the present randomised, double-blind, placebo-controlled trial in seven centres in five West European
countries, 830 healthy term infants, without a first-degree family history of allergic disease, of mothers who indicated to give only formula
feeding were randomised either to receive a standard non-hydrolysed cows’ milk-based formula to which a mixture of specific oligosac-
charides was added (prebiotics group (PG)), or to receive a similar formula without oligosaccharides (control group (CG)). A separate
reference group consisted of 300 breast-fed infants. The primary outcome was the number of fever episodes prospectively documented
by the parents. There was no difference in the number of fever episodes between the PG (median value 1·19; 25th–75th percentile
0·09–2·34) and CG (1·16; 25th–75th percentile 0·06–2·38). The median number of fever episodes in the separate breast-feeding reference
group was 1·24 (25th–75th percentile 0·51–3·45). There was no effect of adding specific prebiotics to standard formula feeding in reducing
the number of fever episodes in the present study.
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Breast-feeding is universally recommended as the optimal
feeding for infants in the first 6 months of life(1,2). There is
clear evidence for health benefits for both mother and child.
Special attention has been given to the effect regarding infec-
tions in young children(3–5). The protective effect of breast-
feeding against infectious diseases is assumed to be provided
by specific (antibody-dependent) and non-specific factors
such as oligosaccharides, proteins, glycoproteins and fats.
Many efforts have been made to make the composition
of formula (e.g. proteins and fats) as close as possible to
breast milk(6,7).
Human milk oligosaccharides, after lactose and lipids,
represent the third largest solid component in breast milk,
and contribute to immune modulation and infection preven-
tion(8,9). They exert prebiotic function by acting as soluble
analogues to epithelial receptors for specific microbes, and
this prevents their adhesion to the intestinal wall(10,11). Further,
they enhance mucosal barrier function with a direct effect on
intestinal maturation and trophic effects on the intestinal
mucosa through their fermentation products(12,13); lower the
pH in the colon through the fermentation products(10,14);
and interact directly with the cells of the immune system(15).
Thus, breast milk oligosaccharides are powerful candidates
to be key components of human milk contributing to its
protective effect against infections in infants. Clinical data
about the effect of oligosaccharide supplementation to
formula feeding on infections in young healthy children are
scarce. Recently, two studies have been published pointing
to a reduction of infections in the early life of infants who
had an increased risk of allergic diseases(16–18). There is no
well-designed study available about its effect in low-allergy-
risk populations. The aim of the present randomised,
double-blind, placebo-controlled, multicentre study was to
evaluate the effect of adding a mixture of specific prebiotics
to standard formula feeding on the number of fever episodes
in the first year of life of healthy term children.
Patients and methods
The present study (Multicenter Infection Prevention Study)
was a randomised, double-blind, placebo-controlled, multi-
centre trial. Participating study centres were the Beatrix
Children’s Hospital in Groningen, The Netherlands (n 207);
the Schwarzach Hospital in Schwarzach, Austria (n 181);
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the University Children’s Hospital in Zu¨rich, Switzerland
(n 163); the Mangiagalli Hospital in Milan, Italy (n 155);
the Macedonio Melloni Hospital in Milan, Italy (n 145); the
Charite´-Universa¨tsmedizin Berlin, in Berlin, Germany (n 143);
the Brescia Hospital in Brescia, Italy (n 136). Parents of
healthy term infants were invited with their child to participate
between July 2005 and December 2007; follow-up ended in
December 2008. Inclusion took place before the postnatal
age of 8 weeks. Parents with babies in their first 8 weeks of
life from the region of the participating centres were informed
about the study in the perinatal centre (Germany), the paedia-
tric outpatient clinic (Italy, Austria, Switzerland), or in the Well
Baby Clinic (The Netherlands). Parents were asked to call
back only if they were interested in the study.
Healthy term infants (gestational age 37–42 weeks) with a
birth weight above the 10th percentile for gestational age
according to locally applicable growth charts were included.
Infants at risk for atopic diseases (having a first-degree relative
to a positive history of asthma, allergic rhinitis or atopic
dermatitis) were excluded(19). Infants with metabolic disorders
requiring a special diet other than standard non-hydrolysed
feeding were excluded. Infants with neonatal diseases requir-
ing antibiotic treatment, congenital diseases or malformations
influencing the gastrointestinal system, and infants who had
used formulas containing prebiotics or probiotics were
excluded. Infants from mothers with known colonisation
with group B streptococci during pregnancy, which often is
an indication for antibiotic treatment, were also excluded.
Infants from mothers who were suffering from HIV or hepatitis
B were also excluded from the study. In Europe, mothers are
not routinely tested for cytomegalovirus and hepatitis C as the
prevalence of both infections in Europe is quite low. Thus,
these were not considered as exclusion criteria. The study
was approved by all local Ethical Review Boards of the parti-
cipating centres, and written informed consent was obtained
from each parent. The present study was registered with the
German Clinical Trials Register DRKS00000201.
Mothers were encouraged to breast feed their infants for at
least 4 months and preferably 6 months. To comply with the
ethical standards not to influence breast-feeding mothers in
any way to use an instant formula instead, mothers were
asked their consent to participate in the study and to be ran-
domised to one of the two formula groups only if they
could not or did not fully breast feed their infants, and who
received at least one bottle of formula before. Only infants
of mothers who indicated before the 8th week after birth to
give only formula feeding at least during the first 4 months
of age were randomised. After randomisation, breast-feeding
could partly be continued; after randomisation, the only sub-
stitute or supplement in case of insufficient breast-feeding
was the randomised study formula. Infants of mothers who
indicated to give full breast-feeding were included in the
non-randomised breast-feeding reference group. In case of
insufficient breast-feeding, supplemental formula feeding
could be given according to the local standards at the parents’
preference. If mothers could not provide enough breast-
feeding any longer, the standard formula available on the
local market was offered.
Randomisation to one of the two formula groups was
performed immediately after study entry. Randomisation was
performed stratified according to study centre. Time-balanced
randomisation was performed with the software RANCODE
(Professional 3.6; idv Data Analysis and Planning, Gauting,
Germany), with a random permuted block size of 4.
Masking of treatment allocation
Only the hospital pharmacist had a copy of the randomisation
list with the actual treatment allocation. The parents, the study
physicians and the study nurses were unaware of the group
allocation. The tins and the milk powder looked and smelled
identical. Infants randomised to the prebiotics group (PG)
received a standard non-hydrolysed cows’ milk-based formula
to which a mixture of specific neutral short-chain galacto-
oligosaccharides and long-chain fructo-oligosaccharides
(ratio 9:1, Immunofortisw; Nutricia Cuijk BV, Cuijk, The
Netherlands) and specific pectin-derived acidic oligosacchar-
ides was added. The total amount of oligosaccharides was
8 g/l, with 6·8 g/l neutral and 1·2 g/l acidic oligosaccharides.
Infants randomised to the control group (CG) received a
similar standard non-hydrolysed cows’ milk-based formula
without added oligosaccharides. For both groups, starter
formula was provided during the first 6 months of life, there-
after follow-on formula was offered. Infants randomised to the
PG continued to receive the oligosaccharides in the follow-on
formula. It was advised not to start weaning from either
exclusive breast-feeding or formula feeding before the age
of 4 months.
Outcome measure
The occurrence of a fever episode was the primary outcome.
The observation period was until the age of 1 year. A diary
provided to the parents at inclusion and filled out by parents
or carers was used to ascertain the number and duration of
fever episodes. Parents were asked to fill in the form every
day their child had fever. They were asked to report next to
fever other symptoms as well. They were instructed to take
their child’s temperature only if they thought the child might
have fever; no further instruction was given in order not to
influence normal parental care. We considered this ‘normal
daily practice at home’ the best condition for performing the
study. We assumed that variations from family to family
about the threshold for taking the temperature would be
equally distributed between the PG and CG by randomisation
(but not in the non-randomised breast-feeding group (BG)).
Fever was defined as a peak rectal temperature $38·58C; a
peak rectal temperature was the highest measured rectal tem-
perature of at least three measurements during a 24 h period.
We calculated a new fever episode if the time without any
symptoms between febrile illnesses was more than 1 day (24 h).
Every 2 weeks (after the age of 16 weeks every 4 weeks)
contact was made with the parents, either by home visits,
clinic visits or phone calls. During these interviews, also
other data, including the occurrence of atopic dermatitis,
were collected; the results have been published separately(20).
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Symptoms which accompanied the fever were registered
based on parental reports. Based on these reports, we
retrospectively made a suspected diagnosis of the cause of
the fever. Gastroenteritis was defined as a fever episode
accompanied by vomiting and diarrhoea, or only diarrhoea.
Upper respiratory tract infection was defined as a fever epi-
sode accompanied by a runny nose with cough or wheeze.
Otitis was defined as a fever episode accompanied by a
painful or discharging ear. Parents were asked to report if
their child had received a vaccination within 3 d before the
fever occurred: this was considered a vaccination-related
fever if no other symptoms were reported. All fever episodes
were counted, irrespective of the associated symptoms or sus-
pected cause. Symptoms were based on the reports of the
parents; a doctor’s diagnosis was not considered necessary.
However, if reported, a doctor’s diagnosis was given priority
to other suspected diagnoses. Systemic antibiotic treatment
during fever was also reported by the parents.
Statistical analysis
In order to detect a mean reduction of one fever episode
(4·5 fever episodes per year in the CG compared with 3·5 in
the PG)(21), with a standard deviation of 3·5, 93 % power
and significance level of 0·05 in a one-sided unpaired t test,
250 formula infants were needed per group. With a 50 %
total dropout rate (expected 35 % mixed feeding and 15 %
dropout for another reason), 500 infants per group had to
be enrolled. After some time, the expectations about the
expected total dropout rate could be adjusted down to
about 40 %. To stay close to the planned timeline, the recruit-
ment was stopped at about 400 infants per group.
All statistical analyses were performed with SASw, version 9
(SAS Institute, Cary, NC, USA). The main outcome variable
was analysed using one-sided testing, which was determined
a priori. All the other analyses were performed using two-
sided testing. Significance level for all testing was 0·05. All ana-
lyses were performed with stratification per centre, unless
numbers were too small.
The primary analyses were performed using the full-
analysis set (FAS), and in some cases also using the per-protocol
set (PPS). The FAS consisted of all children who had been
randomised to the PG or CG, or had been included in the
BG (non-randomised), with the exclusion of the screening
dropouts (within 8 weeks after birth). The PPS consisted
of all children who completed the follow-up until their
first birthday (52 weeks), and had received exclusively the
prebiotic formula feeding, or the control formula feeding,
during the complete follow-up, or had received exclusively
breast-feeding for the first 4 months of life (20 weeks).
Children who were randomised to the PG or CG, and
received additional breast-feeding, were considered as ‘mixed
feeding’ and were analysed in the FAS only, according to
the allocated formula feeding group (either the PG or CG).
This may eventually diminish the magnitude of the hypoth-
esised effect of prebiotics supplementation to infant formula
feeding in the FAS analysis, but not in the PPS analysis.
We collected data about the actual exclusive intake of study
formula feeding (PG and CG) or BG over time in the first
16 weeks, in order to assess the ‘ingested dose’ of prebiotics
in the study groups at a time that no additional other feeding
(fruits, vegetables and bread) was given.
Dropouts were those infants who did not complete the first-
year follow-up, because of (1) change to another formula
(whether or not on the preference of the parents or on
doctors’ advice; change to another formula in the BG indicates
that the breast-feeding was stopped completely before
4 months of age); (2) intolerance to formula (occurrence of
vomiting, flatulence, cramps, colics, nappy rash or diarrhoea);
(3) occurrence of any disease (as a reason to withdraw the
infant from the study on the preference of the parents or on
doctors’ advice); (4) withdrawal (dropout for unknown
reason). All dropouts were analysed in the FAS.
The main outcome variable was the rate of fever episodes
(adjusted) and was defined as (number of fever episodes
þ 0·05)/(duration of observational period þ 0·1). By adding
0·05 and 0·1, the rates have been ranked to be used for statisti-
cal analysis. This adjustment was done in order to prevent
‘zero’ in those cases without any fever episode. Furthermore,
the duration of the observational period has been taken into
account(22). To present the number of fever episodes per
year, this number has been multiplied by 365·1 d. By using
this technique, the number of fever episodes per child could
be taken into account. Similar calculations were done for
the number of suspected causes of fever and associated symp-
toms. This is the reason why those ‘adjusted numbers’ cannot
be added up to calculate the total median adjusted number of
all fever episodes.
Differences in the rate of fever episodes and number
of fever episodes per year were analysed using the non-
parametric van Elteren test for all centres, or the Wilcoxon
rank-sum test for individual centres(23). The analyses were
performed for the first year of life (from inclusion in the
study until the age of 12 months) and in the first half year
(from inclusion in the study until the age of 6 months), both
in the FAS and PPS datasets.
We only tested for any differences in baseline characteristics
between the PG and CG (stratified regression analysis), and
not the BG due to its non-randomised character. Time to
first occurrence of a fever episode and recurrent fever epi-
sodes were analysed using stratified Cox proportional
hazard regression analysis(24). The time to first occurrence of
a fever episode was defined as the time from inclusion to the
day before the first occurrence of a fever episode. If no fever
episode occurred during the observational period, the time to
first occurrence equalled the duration of the observational
period. The end of the observational period was either the
end of the study at the age of 12 months or early dropout
from the study for whatever reason. By analysing the data
using this technique, any time-dependent fluctuation of
the risk of having a fever episode is taken into account. Cox
regression analysis was also used to examine the occurrence
of repeated fever episodes. The counting process model was
used, which assumes that each fever episode is independent
of the other, and that a subject is at risk for a subsequent
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event, even if he had not previously experienced an event,
provided he is still under observation. Since multiple events
were recorded for each subject, the model also accounted
for correlated observations within subjects. To model the
occurrence of repeated events, all baseline variables
(presented in Table 1) were used. A multivariate regression
model was identified including the number of fever episodes
as the dependent variable. A forward stepwise selection
was conducted, with a P value entry criterion of 0·10 and a
stay criterion of 0·10. Due to the non-randomised character,
the BG was not included in this analysis.
Results
From July 2005 to December 2007, 414 infants were ran-
domised to the PG and 416 infants to the CG, and 300
infants were included in the BG which is the non-randomised
reference group (Fig. 1). There was no statistical significant
difference in dropout numbers in the PG v. CG (x 2 test,
P¼0·23).
The baseline characteristics are given in Table 1. There were
no significant differences between the PG and CG. There were
quite some baseline differences between the CG and BG,
as can be expected due to the non-randomised character of
this group (not statistically tested).
Table 2 presents the intake of feeding per study group.
The exclusive intake of formula feeding showed a 10 %
increase over time in the first 16 weeks from about 70 %
up to 80 % in both formula groups. The BG showed a 4 %
decrease in the exclusive intake of breast-feeding from
about 88 to 84 % over time in the first 16 weeks.
Table 3 presents the overall adjusted number of fever
episodes during the first year of life. There was no significant
difference between the PG and CG (median values 1·19 v.
1·16, P.0·05). When only those infants who completed the
study were analysed (PPS), a small but significant difference
in the number of fever episodes was found in the first
6 months in the PG v. CG: (median values 0·13 (25th–75th
percentile 0·12–2·31) v. 0·13 (25th–75th percentile 0·12–
2·36), P,0·05).
Table 4 presents the adjusted number of fever episodes
during the first year of life for all infants for each participating
centre separately. On a centre level, there were no significant
differences between the PG v. CG. There was a significant
difference in the adjusted number of fever episodes in the
first year of life in the CG v. BG in the centres University
Hospital Charite´, Berlin, Germany (1·22 v. 2·36, P,0·05) and
Zu¨rich Children’s Hospital, Zu¨rich, Switzerland (1·26 v. 3·45,
P,0·05).
The hazard ratio (HR) of having a first fever episode was
1·07 (95 % CI 0·90, 1·26) in the PG v. CG. Fig. 2 presents the
Table 1. Baseline characteristics
(Median values, 25th–75th percentiles, number of subjects and percentages)
PG (n 414) CG (n 416) BG (n 300)
Median
25th–75th
percentile n % Median
25th–75th
percentile n % Median
25th–75th
percentile n %
Age at inclusion (d)* 30 20–42 32 21–45 50 36–54
Birth weight (g) 3277 2965–3610 3320 2930–3625 3438 3110–3678
Gestational age (completed weeks) 39 38–40 39 38–40 40 39–40
Boys 220 53 200 48 134 45
White race 378 91 392 94 287 96
Vaginal delivery 261 63 272 65 247 82
Rooms in household (not
kitchen/bathroom)
3 3–4 3 3–4 4 3–5
Number of children in
household
2 1–2 2 1–2 2 1–2
Single-parent family 25 6 23 6 17 6
Furry pets in household 133 32 150 36 95 32
Smoking mother 79 19 81 19 21 7
Smoking father 142 35 163 40 81 27
Education level of the mother
Primary and secondary school 206 50 208 50 115 38
Some university education/some
post-secondary education/
technical or trade qualification
138 33 119 29 107 36
Completed university degree 69 17 89 21 78 26
Mother employed 252 61 269 65 207 69
Education level of the father
Primary and secondary school 184 46 188 46 101 34
Some university education/some
post-secondary education/
technical or trade qualification
142 35 127 31 113 38
Completed university degree 77 19 95 23 85 28
Father employed 369 92 377 92 283 95
PG, prebiotics group; CG, control group; BG, breast-feeding group.
* Age at inclusion is similar to age at start of the study formula (in the PG and CG).
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Kaplan–Meier curve of the analysis of time to first occur-
rence of a fever episode. The Kaplan–Meier analysis showed
a probability of 0·66 of having a first fever episode after
inclusion in the PG, 0·65 in the CG and 0·71 in the BG.
Median survival times were 210, 220 and 208 d, respectively.
Table 5 presents the final results of the multivariate recur-
rent event analysis. Study group was not a significant variable
influencing the rate of fever episodes. The rate of fever
episodes was significantly increased by the variables: male
sex (HR 1·25) and white race (HR 1·42). The rate of fever
episodes was decreased by the presence of furry pets in the
household (HR 0·80).
There was no difference in day-care use (more than six
children in a group) during the complete follow-up between
the PG and CG (repeated-measures logistic regression anal-
ysis, P¼0·26). At the time point of 20 weeks, in the PG
2·2 % of the children used day care; in the CG 2·9 %; and in
the BG 3·2 %; and at 52 weeks, these numbers were 15, 14
and 17 %, respectively.
The total number of fever episodes was 1697, comprising
the following categories of suspected causes of fever and
associated symptoms: upper respiratory tract symptoms (465;
27 %), no symptoms except fever (377; 22 %), other symptoms
(298; 18 %), gastroenteritis symptoms (187; 11 %), ear infection
(119; 7 %), exanthema (117; 7 %), vaccination-related fever
(56; 3%), teething (31; 2 %), pneumonia/bronchiolitis (19; 1 %),
urinary tract infection (15; 1 %), eye infection (12; 0·5 %)
and osteomyelitis (1; 0·1 %). The adjusted number of the
suspected causes of fever and associated symptoms in the
first year of life are presented in Table 6. There were no stat-
istical significant differences between the PG and CG.
The median adjusted numbers of fever episodes for which
systemic antibiotics have been used during the first year of
life were 0·05 (25th–75th percentile 0·05–0·11) in the PG,
0·05 (25th–75th percentile 0·05–0·16) in the CG, and 0·05
(25th–75th percentile 0·05–0·09) in the BG. There was no
statistically significant difference between the PG and CG.
There were no serious adverse events related to the inter-
vention. Details will be published separately.
Assessed for
eligibility (n 1187)
Randomised (n 830)
Screening dropouts (n 57)
Not randomised (n 300)
Allocated to prebiotics group (FAS)
• Received allocated intervention (n 414)
Allocated to control group (FAS)
• Received allocated intervention (n 416)
Dropouts (n 53)
• Change to another formula (n 8)
• Intolerance to formula (n 10)
• Occurrence of any disease (n 7)
• Withdrawal  (n 28)
Analysed as PPS
• Exclusively prebiotic formula (n 292)
• Excluded: mixed feeding (n 69)
Allocated to reference group (FAS) 
• Breast-feeding (n 300)
Completed first year (n 361)
Dropouts (n 42)
• Change to another formula (n 10)
• Intolerance to formula (n 7)
• Occurrence of any disease (n 6)
•  Withdrawal  (n 19)
Completed first year (n 374)
Analysed as PPS
• Exclusively control formula (n 300)
• Excluded: mixed feeding (n 74)
Analysed as PPS
• Exclusively breast-feeding (n 243)
• Excluded: mixed feeding (n 23)
Completed first year (n 266)
Dropouts (n 34)
• Change to another formula (n 11)
• Occurrence of any disease (n 2)
• Withdrawal  (n 21)
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Fig. 1. Flow chart of infants participating in the study. FAS, full-analysis set; PPS, per-protocol set.
Table 2. Exclusive study formula and exclusive breast-feeding per
2-week time point in the first 16 weeks of life
(Number of infants and percentages)
PG (n 414) CG (n 416) BG (n 300)
n % n % n %
8 weeks 286 69·1 284 68·3 264 88·0
10 weeks 301 72·7 309 74·3 264 88·0
12 weeks 325 78·5 332 79·8 264 88·0
14 weeks 321 77·5 333 80·0 256 85·3
16 weeks 340 82·1 343 82·5 253 84·3
PG, prebiotics group; CG, control group; BG, breast-feeding group.
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Discussion
In the present study of healthy term infants, we found no
significant difference in the number of fever episodes between
the PG and CG in the first year of life.
As suspected causes of fever, mainly respiratory tract
infections and gastroenteritis were counted. The frequency
of the suspected causes of fever and associated symptoms
was more or less equally distributed as in other relevant
studies(17,18,21). However, we did not find any differences in
the suspected causes of fever between the PG and CG.
Results of previous studies point to favour children
receiving formula supplied with prebiotics. A randomised,
placebo-controlled, single-centre study of a prebiotic-
supplemented (8 g/l galacto- and fructo-oligosaccharides)
formula showed a significant reduction in the number of
infectious episodes documented by a paediatrician in the
first 6 months in the PG(16). In the follow-up of this cohort, in
addition, the occurrence of fever episodes of$38·58C reported
by the parents was significantly reduced in the PG(17). A Finnish
randomised, placebo-controlled trial of ‘synbiotic’ treatment
of four probiotic species (mothers) and the same probiotics
in addition to 0·8 g/l galacto-oligosaccharides (their infants)
showed a reduction of respiratory infections in the ‘synbiotic’
treatment group. In contrast to the present results, both
studies showed a reduction in the use of antibiotic treat-
ment in the prebiotic and ‘synbiotic’ groups, respectively(17,18).
From the most recent multicentre, open-label, randomised
controlled trial, it is difficult to draw any conclusions because
of the open design and presentation of per-protocol analysis
results only(25). In summary, unlike the present study, these
previous studies showed a reduced number of infections in
infants receiving a formula supplied with prebiotics.
The difference in results may be explained by different
characteristics of the studies. The previous studies mainly
counted physician-diagnosed infections. However, diagnosis
may not play an important role since the incidence of fever
episodes and infections is low. Previous studies included
infants with an increased risk for atopy, probably prone to
respiratory infections. Both previous studies(17,18) showed a
decrease in respiratory infections at 2 years of age indeed.
The present Multicenter Infection Prevention Study popula-
tion is a healthy population: all children were identified by
preventive health care visits, and had a low risk for allergy.
Based on the very low rate of fever episodes in the present
study, we may also consider the study underpowered to
find an effect of the prebiotic mixture on the number of
fever episodes. However, if much more participants would
be necessary to find an effect, the clinical relevance would
be very small. In the additional sub-analysis of the PPS set
Table 3. Adjusted number of fever episodes per year
(Median values, 25th–75th percentiles and number of infants)
PG CG BG
Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
FAS
n 414 416 300
Follow-up time
Inclusion – 12 months of age 1·19 0·09–2·34 1·16 0·06–2·38 1·24 0·51–3·45
Inclusion – 6 months of age 0·13 0·12–2·31 0·13 0·12–2·36 0·14 0·13–2·63
PPS
n 292 300 243
Follow-up time
Inclusion – 12 months of age 1·19 0·09–2·34 1·16 0·06–2·38 1·24 0·51–3·45
Inclusion – 6 months of age 0·13 0·12–2·31 0·13* 0·12–2·36 0·14 0·13–2·63
PG, prebiotics group; CG, control group; BG, breast-feeding group; FAS, full-analysis set; PPS, per-protocol set.
* Median value was significantly different from that of the PG (P,0·05).
Table 4. Adjusted number of fever episodes per year per study centre
(Median values, 25th–75th percentiles and number of infants)
PG (n 414) CG (n 416) BG (n 300)
n Median
25th–75th
percentile Median
25th–75th
percentile Median
25th–75th
percentile
Beatrix Children’s Hospital, Groningen, The Netherlands 207 1·21 0·49–2·70 1·21 0·06–2·39 1·20 0·06–2·23
Schwarzach Hospital, Schwarzach, Austria 181 1·20 1·09–2·35 1·20 0·32–3·25 1·24 0·70–3·34
University Children’s Hospital, Zu¨rich, Switzerland 163 1·76 0·27–3·30 1·26 0·06–3·07 3·45* 1·23–5·01
Mangiagalli Hospital, Milan, Italy 155 0·53 0·05–2·14 1·07 0·05–2·18 0·83 0·06–1·13
Macedonio Melloni Hospital, Milan, Italy 145 1·22 0·06–2·28 1·13 0·05–2·25 3·29 0·13–3·92
Charite´ Universita¨tsmedizin, Berlin, Germany 143 2·15 1·15–3·22 1·22 0·36–2·38 2·36* 1·20–4·69
Brescia Hospital, Brescia, Italy 136 1·05 0·06–1·25 1·10 0·06–2·27 1·21 0·06–2·39
Total 1130 1·19 0·09–2·34 1·16 0·06–2·38 1·24* 0·51–3·45
PG, prebiotics group; CG, control group; BG, breast-feeding group.
* Median values were significantly different from those of the CG (P,0·05).
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for the first 6 months of life, we found a significant but very
small difference in the number of fever episodes in the first
6 months in the PG v. CG (both median values 0·13) in
favour of the PG. These median values are equal, but a statisti-
cal significant difference exists, which is possible because of
the non-parametric nature of the test. However, the difference,
although significant, is probably not clinically relevant. The
low incidence of fever episodes in the present study also
plays a role. We may hypothesise about an effect only existing
at the time when intake of formula is high and less diluted by
other feedings. In the present study, the actual use of the study
formula, and thus the magnitude of the ingested dose in the
first 16 weeks, was similar in the PG and CG. Between 70
and 80 % of the infants received the study formula only.
A minority of 20–30 % received additional breast milk. This
may have influenced the study results in diluting the beneficial
effect of the prebiotic mixture, if any: prebiotics have been
provided to the infants randomised to the CG by this addi-
tional breast milk.
Overall, the number of fever episodes per year is much
lower than we had expected previously(21). In the study of
Wald, in which type of nutrition was not accounted for,
children in a home care setting showed 4·7–7·1 infections in
the first year of life, depending on setting of care. Upper res-
piratory tract infections accounted for almost 85 % of all infec-
tions; and nasal discharge or nasal congestion was considered
to be an infection. Severe infections, defined as fever higher
than 39·08C, or a doctor’s consult, occurred 2–3·5 times in
the first year of life in infants. These results may indicate
that fever episodes are a more robust indicator of an infection
compared with other symptoms in the first year of life. Fever
episodes reported by the parents as an indicator of infection
have been presented in a few other studies. A recent study
presented a number of 0·1–0·4 fever episodes per child in
12 weeks in healthy term children aged 4–10 months in day-
care centres in Israel(26). The study of Arslanoglu presented 3·9
(placebo group) v. 2·2 (PG) fever episodes in 2 years in
children with an increased risk of atopy. In this study, it has
not been documented whether fever was an accompanying
symptom of infections diagnosed by a physician. A compari-
son with the present data cannot be made easily(17). We may
hypothesise about a decreasing occurrence of infections in
the first year of life in the relatively rich parts of the world.
An explanation might be the introduction of vaccinations
against Haemophilus influenzae type B and Streptococcus
pneumoniae, as well as improved socio-economic factors
and possibly nutritional habits. In case of this situation of low
numbers of fever episodes in the first year of life of healthy
term children, nutritional interventions, such as prebiotic
supplementation, may not have an additional substantial redu-
cing effect. Some differences regarding fever episodes
between countries existed: in Berlin, Germany, and Zu¨rich,
Switzerland, higher numbers of fever episodes in the BG were
reported. We do not know why such a difference exists
between countries, but reporting bias in the sense of a
higher level of recognising and reporting of fever in the BG
in these countries could definitely play a role.
In contrast to the hypothesised decreasing number of
infections, there is strong evidence of an increase in allergic
symptoms in young children(27) (http://www.cdc.gov/asthma).
Studies have suggested a role of prebiotics in the prevention of
atopic dermatitis(17,20,28) (http://www.cdc.gov/asthma).
Regression analysis revealed factors influencing the number
of fever episodes in the present study. Males had a higher
number of fever episodes than females (about 25 %), white
children had a higher number of fever episodes than others
(about 40 %), and children in households with a furry pet
had a lower number of fever episodes (about 20 %). Being a
boy (compared with being a girl) was the only factor ident-
ified in another study previously(20). To our knowledge, the
presence of furry pets in the household was not identified
earlier as a factor influencing (that is reducing) the number
of fever episodes. Ethnicity was identified as a factor influen-
cing the number of fever episodes in the present study.
However, the prevalence of different ethnicities was very
low in the present study (Table 1), so this factor should be
interpreted with care.
In contrast to previous findings, the present data suggest a
higher number of fever episodes in the BG. An explanation
might be that parents in the BG may have a higher awareness,
or a more precise way, to recognise and report fever in
their child compared with parents giving formula feeding.
A higher education level of parents choosing to give breast-
feeding may be a part of the explanation for this ‘reporting
bias’. In the present study, breast-fed infants lived in relatively
Table 5. Multivariate regression analysis of recurrent event analysis –
final model
(Hazard ratios (HR) and 95 % confidence intervals)
HR 95 % CI
Boys 1·25 1·08, 1·43
White race 1·42 1·07, 1·87
Furry pets in the household 0·80 0·68, 0·94
Study group
Prebiotics group 0·99 0·86, 1·14
Control group Reference category
1·0
0·8
0·6
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Fig. 2. Cumulative probability over time of a first fever episode by treatment
group (full-analysis set). Prebiotics group ( ), control group ( ) and breast-
feeding group ( ).
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healthy circumstances (Table 1). In previous studies, similar
differences between breast-fed and formula-fed infants were
found(3,4). We may hypothesise that, assuming that nowadays
in the relatively rich parts of the world, socio-economic
(hygiene) standards are above a certain level for healthy
term children in general, this surplus of healthy circumstances
in breast-fed children, or the breast-feeding itself, does not
protect against infections at a scale high enough to be
detected anymore. This lack of effect of type of feeding on
the number of fever episodes may be reassuring for mothers
who for any reason are not able to provide breast milk to
her child. Follow-up studies are needed to evaluate if there
is an effect at an older age. Previous studies have compared
the frequency of infections in breast-fed and formula-fed
healthy term infants, all showing a lower number of infections
in breast-fed children. Difficulties in interpreting these results
arise from studies presenting a positive effect on a selection of
symptoms and age categories only(3,5,29), some studies do
not report a comparison with formula feeding(30), or do not
present data about the prevalence of breast-feeding in the
study population(29) and one study showed a large reducing
effect of exclusive and prolonged breast-feeding for 6 months
on hospitalisation frequency; in this study population, there
was a high estimated hospitalisation frequency but a low
prevalence of exclusive and prolonged breast-feeding for at
least 6 months(5). Due to the non-randomised character of
the BG in all these previous studies and the present study,
it remains difficult to quantify the effect of breast-feeding on
the number of infections in healthy term infants in low-risk
parts of the world. Irrespective of the difficulty to show
high-level evidence, as clinicians, we certainly do agree
with the international guidelines to promote breast-feeding
for all infants(1,2).
Conclusion
In the present study, specific prebiotics added to standard
formula feeding do not decrease the number of fever episodes
in the first year of life in healthy term infants. If there is an
effect, it probably is very small and clinically of minor relevance.
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Table 6. Adjusted number of suspected causes of fever and associated symptoms per year
(Median values and 25th–75th percentiles)
PG (n 414) CG (n 416)* BG (n 300)
FAS Median 25th–75th percentile Median 25th–75th percentile Median 25th–75th percentile
Upper respiratory tract infection 0·05 0·05–1·03 0·05 0·05–1·03 0·05 0·05–1·04
No symptoms except fever 0·05 0·05–0·33 0·05 0·05–0·27 0·05 0·05–1·03
Other symptoms 0·05 0·05–0·14 0·05 0·05–0·16 0·05 0·05–1·01
Gastroenteritis 0·05 0·05–0·09 0·05 0·05–0·07 0·05 0·05–0·05
Ear infection 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Viral exanthema 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Vaccination-related fever 0·05 0·05–0·05 0·06 0·05–0·05 0·06 0·06–0·05
Teething 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Pneumonia/bronchiolitis† 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Urinary tract infection† 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Eye infection 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
Osteomyelitis† 0·05 0·05–0·05 0·05 0·05–0·05 0·05 0·05–0·05
All fever episodes 1·19 0·09–2·34 1·16 0·06–2·38 1·24 0·51–3·45
PG, prebiotics group; CG, control group; BG, breast-feeding group; FAS, full-analysis set.
* Median values were not significantly different from those of the PG (one-sided van Elteren test).
† Doctor’s diagnosis only.
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